Surmodics Statistics
Share Statistics
Surmodics has 14.3M
shares outstanding. The number of shares has increased by 0.24%
in one year.
| Shares Outstanding | 14.3M |
| Shares Change (YoY) | 0.24% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 84.13% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 82 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 476.51K, so 3.33% of the outstanding
shares have been sold short.
| Short Interest | 476.51K |
| Short % of Shares Out | 3.33% |
| Short % of Float | 3.46% |
| Short Ratio (days to cover) | 5.56 |
Valuation Ratios
The PE ratio is -47.55 and the forward
PE ratio is 118.09.
Surmodics's PEG ratio is
-0.07.
| PE Ratio | -47.55 |
| Forward PE | 118.09 |
| PS Ratio | 4.35 |
| Forward PS | 2.9 |
| PB Ratio | 4.62 |
| P/FCF Ratio | -169.19 |
| PEG Ratio | -0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Surmodics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.96,
with a Debt / Equity ratio of 0.28.
| Current Ratio | 3.96 |
| Quick Ratio | 3.22 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 7.03 |
| Debt / FCF | -10.25 |
| Interest Coverage | -1.59 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $324,107.97 |
| Profits Per Employee | $-29,670.95 |
| Employee Count | 389 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 2.18 |
Taxes
| Income Tax | 4.04M |
| Effective Tax Rate | -53.77% |
Stock Price Statistics
The stock price has increased by -15.52% in the
last 52 weeks. The beta is 1.32, so Surmodics's
price volatility has been higher than the market average.
| Beta | 1.32 |
| 52-Week Price Change | -15.52% |
| 50-Day Moving Average | 28.91 |
| 200-Day Moving Average | 35.98 |
| Relative Strength Index (RSI) | 45.99 |
| Average Volume (20 Days) | 156,164 |
Income Statement
In the last 12 months, Surmodics had revenue of 126.08M
and earned -11.54M
in profits. Earnings per share was -0.82.
| Revenue | 126.08M |
| Gross Profit | 93.05M |
| Operating Income | -5.64M |
| Net Income | -11.54M |
| EBITDA | 4.73M |
| EBIT | -3.97M |
| Earnings Per Share (EPS) | -0.82 |
Full Income StatementBalance Sheet
The company has 36.12M in cash and 33.24M in
debt, giving a net cash position of 2.87M.
| Cash & Cash Equivalents | 36.12M |
| Total Debt | 33.24M |
| Net Cash | 2.87M |
| Retained Earnings | n/a |
| Total Assets | 163.21M |
| Working Capital | 57.8M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 248K
and capital expenditures -3.49M, giving a free cash flow of -3.24M.
| Operating Cash Flow | 248K |
| Capital Expenditures | -3.49M |
| Free Cash Flow | -3.24M |
| FCF Per Share | -0.23 |
Full Cash Flow StatementMargins
Gross margin is 73.81%, with operating and profit margins of -4.48% and -9.15%.
| Gross Margin | 73.81% |
| Operating Margin | -4.48% |
| Pretax Margin | -5.95% |
| Profit Margin | -9.15% |
| EBITDA Margin | 3.75% |
| EBIT Margin | -4.48% |
| FCF Margin | -2.57% |
